# Urofollitropin

## Fostimon inj 75 IU

| TAH Drug Code      | [IFOS75](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IFOS75)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Multifollicular development during assisted reproductive technology Ovulation induction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | Multifollicular development during assisted reproductive technology (ART): IM， SUBQ: A starting dose of 150 to 225 units once daily (either starting ~2 weeks after initiating treatment with GnRH agonist， or on the second or third day of the menstrual cycle) until sufficient follicular development is attained (eg， follicular growth and/or serum estradiol levels indicate an adequate ovarian response). May adjust dose based upon ovarian response; maximum: 450 units/day. Ovulation induction: IM， SUBQ: Initial: 75 to 150 units once daily (start within the first 7 days of menstruation). Increase dose by 37.5 to 75 units every 7 to 14 days until adequate response (eg， follicular growth and/or serum estradiol levels indicate an adequate ovarian response); maximum: 225 units/day. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Adverse Effects    | 1% to 10%: Gastrointestinal: Abdominal distention， constipation Genitourinary: Ovarian hyperstimulation syndrome Nervous system: Headache， pain <1%: Dermatologic: Erythema of skin， pruritus Endocrine & metabolic: Hot flash， hyperthyroidism Gastrointestinal: Abdominal pain， dyspepsia， nausea Genitourinary: Breast hypertrophy， cystitis， mastalgia Hematologic & oncologic: Prolonged bleeding time Local: Injection-site reaction (including erythema at injection site， hematoma at injection site， and pain at injection site) Nervous system: Dizziness， emotional lability， fatigue， lethargy Respiratory: Dyspnea， epistaxis                                                                                                                                                           |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| More Info          | [UpToDate](https://www.uptodate.com/contents/urofollitropin-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

